A Trial of HTI-1090 in Subjects With Advanced Solid Tumors

Summary

IDO1 is expressed in a wide variety of human tumors (eg. bladder, breast, colon, DLBCL, HNSCC, lung, ovarian, uterine, renal…), and contributes to tumoral resistance. HTI-1090 (also referred as SHR9146 in nonclinical study reports) is an orally bioavailable, highly potent, novel small-molecule IDO1/TDO dual inhibitor, with favorable preclinical oral bioavailability and safety profiles.

Timeline

Start

2017-08-30

Primary completion

2018-11-01

Completion

2019-01-23

Drugs

Indications